Key Highlights
- Virax Biolabs secured an exclusive distribution partnership with Fosun Diagnostics spanning six countries in Southeast Asia
- The partnership involves the company’s ImmuneSelect immune profiling products designed for research applications
- Tuberculosis research in Thailand will serve as the initial market entry point before regional expansion
- Fosun Diagnostics operates under Fosun Pharma, a healthcare giant with approximately $5.8 billion in 2025 revenues
- VRAX shares exploded more than 241% following the announcement; the company maintains a market capitalization of only $2.53M
On July 9, 2026, Virax Biolabs (VRAX) revealed that its United Kingdom-based subsidiary entered into an exclusive multi-territory commercial distribution agreement with Fosun Diagnostics. The announcement triggered a massive 241%+ surge in VRAX shares during trading.
Virax Biolabs Group Limited, VRAX
The partnership encompasses distribution rights for Virax’s ImmuneSelect product portfolio — a suite of research-grade immune profiling tools — throughout six key Southeast Asian territories: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia.
Fosun Diagnostics operates as part of Fosun Medtech, which falls under the Fosun Pharma umbrella. With Fosun Pharma reporting 2025 revenues of RMB 41.662 billion (approximately $5.8 billion), Virax has secured a financially robust distribution channel throughout the region.
According to the agreement structure, Virax will fulfill orders for products such as ELISpot assay plates — specialized tools for analyzing cellular immune responses — based on purchase orders submitted by Fosun. The pricing model incorporates volume-based discount tiers.
The collaboration launches immediately with product supply capabilities and initially concentrates on tuberculosis research applications within Thailand, subsequently rolling out to the remaining five territories.
The exclusive distribution rights depend on meeting specified minimum purchase volumes and performance benchmarks. Should these targets fall short, the exclusivity provisions may be subject to modification.
The agreement structure also allows for future expansion possibilities, including additional product lines, increased supply volumes, and potential original equipment manufacturer (OEM) or white-label arrangements.
Understanding ImmuneSelect
ImmuneSelect represents Virax’s market-ready research-use-only product portfolio. This differs significantly from ViraxImmune, the company’s diagnostic platform currently undergoing clinical trials and regulatory approval processes.
This differentiation is critical. ImmuneSelect has achieved commercial availability and is attracting business interest. ViraxImmune remains in the development pipeline.
James Foster, Chairman and CEO of Virax Biolabs, described the partnership as “a major step forward in the commercial rollout” of the ImmuneSelect technology throughout Southeast Asia.
Leon Zhang, who serves as International Commercial Head for China Domestic Business at Fosun MedTech, indicated that Fosun is examining ELISpot-based research opportunities across the regional markets.
VRAX Stock Overview
Virax Biolabs operates with a market capitalization of merely $2.53 million, placing it firmly in micro-cap territory. Daily trading volume averages approximately 1.05 million shares.
The latest analyst coverage assigns VRAX a Buy rating with a $1.00 price target.
Technical indicators currently show a Sell signal for the stock, which contrasts sharply with today’s dramatic upward movement.
The 241%+ price surge places the stock under intense scrutiny, although extreme volatility on news catalysts is typical for companies at this market capitalization level.
As of July 9, 2026, the supply arrangement is operational and Fosun can begin submitting purchase orders immediately under the terms of the agreement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
